Overview

Efficacy and Safety of TQB2618 Injection Combined With Terriprizumab Injection in Patients With Advanced Melanoma

Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This study is an open, single-center, multi-cohort phase Ib exploratory study, and 50 subjects are planned to be enrolled to observe the objective response rate of each subject. The safety evaluation of this study adopts common terminology criteria for adverse events version 5.0 standard to evaluate the adverse events of drugs.Efficacy was evaluated using response evaluation criteria in solid tumors version 1.1 and efficacy was confirmed using response evaluation criteria in solid tumors for immune-based therapeutics criteria
Phase:
Phase 1
Details
Lead Sponsor:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.